Repositorio Dspace

Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study

Mostrar el registro sencillo del ítem

dc.contributor.author Cortes-Hernández, Josefina
dc.contributor.author Marras-Fernández-Cid, Carlos
dc.contributor.author Andreu-Sánchez, José-Luis
dc.contributor.author Calvo-Alen, Jaime
dc.contributor.author García-Aparicio, Ángel-M
dc.contributor.author Díez-Álvarez, Elvira
dc.contributor.author Hidalgo-Bermejo, Francisco-Javier
dc.contributor.author Coronell, Carlos
dc.contributor.author Perna, Alessandra
dc.contributor.author Ordi-Ros, Josep
dc.date.accessioned 2025-12-03T11:13:22Z
dc.date.available 2025-12-03T11:13:22Z
dc.date.issued 2023-06
dc.identifier.citation Cortés-Hernández J, Marras Fernández-Cid C, Andreu Sánchez JL, Calvo Alén J, García-Aparicio AM, Díez Álvarez E, et al. Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study. Reumatología Clínica. junio de 2023;19(6):312-8.
dc.identifier.issn 1699-258X
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/22958
dc.description.abstract INTRODUCTION AND OBJECTIVES: This OBSErve Spain study, a part of the international OBSErve programme, evaluated belimumab real-world use and effectiveness following 6 months of treatment in patients with active systemic lupus erythematosus (SLE) in clinical practice in Spain. MATERIALS AND METHODS: In this retrospective, observational study (GSK Study 200883), eligible patients with SLE receiving intravenous belimumab (10mg/kg) had their disease activity (physician assessed), SELENA-SLEDAI scores, corticosteroid use, and healthcare resource utilisation (HCRU), assessed after 6 months of treatment versus index (belimumab initiation) or 6 months pre-index. RESULTS: Overall, 64 patients initiated belimumab, mainly due to ineffectiveness of previous treatments (78.1%) and to reduce corticosteroid use (57.8%). Following 6 months of treatment, 73.4% of patients achieved ?20% overall clinical improvement, while only 3.1% of patients worsened. Mean (standard deviation, SD) SELENA-SLEDAI score decreased from 10.1 (6.2) at index to 4.5 (3.7) 6 months post-index. HCRU decreased from 6 months pre-index to 6 months post-index, with fewer hospitalisations (10.9% vs 4.7% patients) and ER visits (23.4% vs 9.4% patients). Mean (SD) corticosteroid dose decreased from 14.5 (12.5)mg/day at index to 6.4 (5.1)mg/day 6 months post-index. CONCLUSIONS: Patients with SLE receiving belimumab for 6 months in real-world clinical practice in Spain experienced clinical improvements and a reduction in HCRU and corticosteroid dose.
dc.language.iso eng
dc.publisher ELSEVIER ESPANA SLU
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional 
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0 * 
dc.subject.mesh Humans
dc.subject.mesh Immunosuppressive Agents/adverse effects
dc.subject.mesh Retrospective Studies
dc.subject.mesh Spain
dc.subject.mesh Treatment Outcome
dc.subject.mesh Adrenal Cortex Hormones/therapeutic use
dc.subject.mesh Lupus Erythematosus, Systemic/drug therapy
dc.subject.mesh Patient Acceptance of Health Care
dc.title Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 37286267
dc.relation.publisherversion https://linkinghub.elsevier.com/retrieve/pii/S1699258X22001589
dc.identifier.doi 10.1016/j.reuma.2022.08.001
dc.journal.title Reumatologia Clinica
dc.identifier.essn 1885-1398


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional  Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional 

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta